An Exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
A 3-way cross-over trial of two weeks of treatment with three drug conditions. AZD3480 will
be given in doses of (A) 5mg/day, (B) 50 mg/day and (C) placebo to 24 non-smoking adults with
DSM-IV confirmed ADHD. Three week washout between each treatment period. CYP2D6 genotyping
will be completed at screening and slow metabolisers will be excluded from participation in
this study. Cognitive, ADHD symptom, safety and pharmacokinetic (PK) assessments will be made
during each treatment period. Safety and tolerability assessments will be a major component
of the trial and all serious adverse events (SAE) will be immediately (within 24 hours)
reported to both Targacept and to AstraZenca.